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Assessment of Bleed Scores
Apostolakis et al. used the vitamin K antagonist (VKA) arm of the
AMADEUS trial to assert the superiority of the HAS-BLED
bleeding risk–prediction scheme over the HEMORR2HAGES
and ATRIA schemes (1–4). Deficiencies in their study’s design
nd analysis undermine this assertion.
First, their primary endpoint was clinically relevant bleeding (1)
when the appropriate endpoint is major bleeding. The bleeding
risk–prediction schemes, including HAS-BLED, were developed to
predict major bleeding to help guide the anticoagulation decision in
atrial fibrillation (AF). “Clinically relevant” bleeding is overwhelm-
ingly composed of nonmajor bleeds. Although such events reduce
patient persistence on anticoagulants, they are not comparable in
impact to major bleeds and have little role in the anticoagulation
decision. Trials of novel anticoagulant agents included nonmajor
bleeds in their safety endpoint to increase the sensitivity of detecting
a difference in bleeding risk versus VKAs, not because of the clinical
importance of these events. When Apostolakis et al. restricted their
analysis to major bleeding, the 3 schemes were similar in performance.
Importantly, there were only 39 major bleeding events in the VKA
arm. The authors do not report results from the idraparinux arm of
the AMADEUS trial although there were 2.5 times as many major
bleeds in that cohort (5). Precision is also a concern with the authors’
assertion that the HAS-BLED scheme predicted intracranial hemor-
rhage. Few details of this analysis are provided. The AMADEUS trial
reported only 9 intracranial hemorrhages in the VKA arm. Were the
authors’ analyses based on just 9 events?
HAS-BLED is distinctive in using “INR lability” as a predictor.
There are strong arguments against including international normal-
ized ratios (INRs) in bleeding risk–prediction schemes. First, there are
no INRs available to the patient considering starting VKAs and, second,
INRs are not applicable to novel anticoagulant agents. Furthermore, the
use by Apostolakis et al. (1) of INRs likely biases the data in favor of the
HAS-BLED score. For the HEMORR2HAGES and ATRIA scores,
he authors include only baseline predictor values but for HAS-
LED, they include postbaseline information (i.e., INR values).
very variable included in HAS-BLED is included in the
EMORR2HAGES scheme except for INR lability. Presumably, this
questionable use of postbaseline INR values accounts for the difference in
performance between the 2 schemes.
The bleeding risk–prediction schemes are multipoint scores. A
fair assessment would test the entire range of the point scores for
each scheme both for c-indexes and for Cox models.
More generally, the bleed risk-prediction schemes were
developed on AF cohorts in clinical care and meant to apply to
patients in clinical care. Clinical trials generally exclude patients
who have abnormal bleed score variables, thereby providing an
inadequate test of score performance. Empirically, 77% of patients
in AMADEUS had HEMORR2HAGES scores of 1, a mark-edly left-shifted distribution compared with the original
HEMORR2HAGES cohort (3).
Although the AMADEUS trial is suboptimal for assessing
leed risk–prediction schemes, the authors could begin to address
ur concerns by assessing performance in both the idraparinux and
KA arms in AMADEUS, excluding INR values, including the
ntire range of point scores for each risk scheme, and restricting
he endpoint to major hemorrhage.
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The Analysis of Bleeding
Risk–Prediction Scores
Should Include All Major Bleeds
The study by Apostolakis et al. (1) compares the performance of
bleeding risk–prediction scores in AMADEUS participants ran-
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January 29, 2013:479–84domized to receive a vitamin K antagonist but excludes the 2,283
participants who were randomized to receive idraparinux. Because
most of the bleeds in AMADEUS occurred in participants
randomized to receive idraparinux, the authors should also provide
c-statistics for major bleeding from these participants. For a valid
comparison, could they also provide c-statistics for major bleeding
from AMADEUS participants randomized to vitamin K antago-
nists, using each prediction score as a continuous variable but not
including INR variability? This variable is not available until after
the decision to initiate a vitamin K antagonist has already been
made.
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Reply
Dr. Singer and Drs. Gage and Radford dispute our use of
“clinically relevant bleeding” as a safety endpoint, but this was the
primary safety endpoint of the AMADEUS trial (1). Similarly, in
the recent ROCKET AF trial, the primary safety endpoint was the
composite of “major and clinically relevant non-major bleeding”
(2). Our published analysis already included data on major bleed-
ing while taking warfarin, but ultimately, clinically relevant bleed-
ing would be highly relevant to patients and clinicians who wish to
assess, in an informed manner (rather than by using guesswork),
those who are at risk of important bleeding events in everyday
clinical practice (3). Indeed, clinically relevant bleeding is indeed a
sensible and medically meaningful endpoint, both for patients and
physicians; in the AMADEUS trial, this robust endpoint was also
centrally and blindly adjudicated.
Dr. Singer and Drs. Gage and Radford request the data from
the idraparinux arm of the AMADEUS trial, and these have
recently been published as a separate analysis (4). We did not feel
that these data should be mixed with the warfarin data in our
primary paper (1), given the significant differences between the 2
arms in the number of bleeding events. Furthermore, the devel-
opment of idraparinux has ceased, and we made the pragmatic
decision that clinicians would be more interested in the perfor-
mance of these scores in warfarin-treated patients.
The analysis on intracranial bleeding is based on a small
number of events, as is always the case in assessment of rare
outcomes. Nevertheless, the retrieved area under the curve inreceiver-operator characteristic curve analysis provided accept-
able confidence intervals and a type I error probability of 3%.
The comments by Dr. Singer and Drs. Gage and Radford on
the clinical use of the HAS-BLED score are misinformed. The
“Labile INR” criterion (the L in HAS-BLED) only applies in a
patient already taking wafarin. If the HAS-BLED score is being
used to assess a nonanticoagulated patient’s potential bleeding
risk, then the labile INR criterion does not apply (and scores
zero). In its original validation paper, the c-indexes for HAS-
BLED in patients while taking vitamin K antagonists (VKA)
(0.72), as well as those on antiplatelet agents alone or no
antithrombotic therapy, were provided (c-indexes 0.91 and
0.85, respectively) (5). In addition, the labile INR criterion does
not apply with the non-VKA anticoagulants, but our validation
of the bleeding risk–prediction scores on idraparinux again
clearly shows the value of HAS-BLED in non-VKA
anticoagulation-treated patients (4).
However, risk assessment (whether for stroke or bleeding) is a
dynamic process and should be repeated at regular intervals after
the patient has begun antithrombotic therapy. This is when the
labile INR criterion should be applied (especially because INR
values should be available).
The HAS-BLED score has been shown to outperform the
more complex HEMORR2HAGES and less practical ATRIA
scores in other ‘real-world’ nontrial cohorts, even when major
bleeding was the comparative endpoint (6,7). The limitations of
he ATRIA score have also been highlighted previously (8).
Furthermore, a high HAS-BLED score (3) is predictive of
serious bleeding during bridging therapy, both in patients with
atrial fibrillation and those without (9).
How should HAS-BLED be used? A high HAS-BLED score
(3) is indicative of the need for regular review and follow-up but
should not be used as a reason for withholding or stopping oral
anticoagulation per se. The HAS-BLED score also makes clini-
cians think about the potentially correctable risk factors for
bleeding; for example, uncontrolled blood pressure (the H in
HAS-BLED), labile INRs if on warfarin (the L in HAS-BLED),
and concomitant use of aspirin/NSAIDs or excessive alcohol use
(the D in HAS-BLED). Finally, use of the HAS-BLED score has
been advocated in various international guidelines and consensus
documents [10–12].
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